Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2013, Pages 179-187

  Wu, Jia ^a   Jia, Li Tao ^a   Shao, Li Ming ^a   Chen, Jia Min ^a   Zhong, Dan Dan ^a   Xu, Song ^a   Cai, Jian Ting ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clopidogrel; CYP2C19; Drug drug interaction; Rabeprazole

Indexed keywords

ADENOSINE DIPHOSPHATE; CARBOXYLIC ACID; CLOPIDOGREL; CLOPIDOGREL DERIVATIVE; CYTOCHROME P450 2C19; DRUG METABOLITE; RABEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2C19 GENE; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TURBIDIMETRY; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84873734441     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1329-z     Document Type: Article

References (35)

1. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation 118:1894-1909
2. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S (2011) Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 123:1108-1115
3. van Werkum JW, ten Berg JM, Bredenoord AJ (2009) Proton pump inhibitors and clopidogrel: a difficult dilemma. Am Heart J 157:e43
4. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937-944
5. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260
6. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713-718
7. Kwok CS, Loke YK (2010) Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 31:810-823
8. van Oijen MG, Siersema PD (2011) Effects of proton pump inhibitors in patients receiving clopidogrel: meta-analysis versus clinical practice. Drug Saf 34:173
9. Delavenne X, Basset T, Zufferey P, Malouk N, Laporte S, Mismetti P (2010) Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. J Sep Sci 33:1968-1972
10. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A (2008) Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 48:1219-1224
11. Fernando H, Dart AM, Peter K, Shaw JA (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105:933-944
12. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
13. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2 C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247 (Pubitemid 44497506)
14. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA (2009) Association of cytochrome P450 2 C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
15. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727 (Pubitemid 32783506)
16. Pezalla E, Day D, Pulliadath I (2008) Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 52:1038-1039
17. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148
18. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, von Beckerath N (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714-719
19. Lou HG, Yuan H, Ruan ZR, Jiang B (2010) Simultaneous determination of paracetamol, pseudoephedrine, dextrophan and chlorpheniramine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:682-688
20. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946-2950 (Pubitemid 41612296)
21. Tantry US, Kereiakes DJ, Gurbel PA (2011) Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 4:365-380
22. Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY (2011) Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 46:39-45
23. Gurbel PA, Tantry US (2011) Antiplatelet therapy: clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol 8:7-8
24. Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS (2012) Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients of acute coronary syndrome in Taiwan. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2012.04250.x
25. Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, Botker HE, Sorensen HT, Baron JA (2012) Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 35:165-174
26. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120:2322-2329
27. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48:475-484 (Pubitemid 351389118)
28. Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M (2010) Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 125:e51-54
29. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436 (Pubitemid 350154353)
30. Kim KA, Park PW, Hong SJ, Park JY (2008) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236-242
31. Umemura K, Furuta T, Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6:1439-1441 (Pubitemid 352016331)
32. Ohbuchi M, Noguchi K, Kawamura A, Usui T (2012) Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica 42:633-640
33. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefevre T, Drouet E, Mulak G, Bataille V, Ferrieres J, Verstuyft C, Danchin N (2011) Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2 C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of acute ST-Elevation and Non-ST-elevation myocardial infarction (FAST-MI) registry. Circulation 123:474-482
34. Li XQ, Andersson TB, Ahlstrom M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827 (Pubitemid 38955611)
35. Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 32:365-379